Chiglitazar, an orally available small molecule pan-PPAR agonist (i.e., simultaneous activation of PPARα, δ, and γ), has shown efficacy in the treatment of type 2 diabetes and nonalcoholic steatohepatitis 19. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.